Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia

2. November 2026 aktualisiert von: LAI KWAN LAM, Chinese University of Hong Kong

Enhancing Cardiometabolic Health in Postnatal Women at High-Risk for Preeclampsia Through Exercise Intervention

Women who develop hypertensive disorders of pregnancy have an increased risk of cardiovascular disease later in life. Whether exercise during the postpartum period improves cardiometabolic health in this population remains unclear.

This pilot randomized controlled trial will recruit 40 women who were identified as being at high risk for preeclampsia during pregnancy and subsequently developed a hypertensive disorder of pregnancy. Participants will be enrolled 6 to 8 weeks after delivery and randomly assigned to a 12-week exercise program or standard postnatal care. The exercise program will consist of three sessions per week combining moderate-intensity aerobic exercise, resistance training, and pelvic floor exercises.

Cardiovascular function, blood pressure, blood markers of cardiometabolic health, physical fitness, and body composition will be assessed before and after the 12-week period. Changes in mood, sleep quality, and health-related quality of life will also be evaluated. The study will provide preliminary evidence on the effects of postpartum exercise in this population and inform the design of a larger trial.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

40

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Hong Kong
      • Hong Kong, Hong Kong, Hongkong
        • Rekrutierung
        • Department of Obstetrics & Gynaecology, Prince of Wales Hospital
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 45 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Aged 18 to 45 years.
  • Identified as being at high risk for preeclampsia during the most recent pregnancy and developed a hypertensive disorder of pregnancy (HDP).
  • Had a singleton pregnancy.
  • 6 to 8 weeks postpartum at enrollment.
  • Physically able to participate in the exercise training program.
  • Willing to participate in the study and provide informed consent.

Exclusion Criteria:

  • Had a multiple pregnancy.
  • Severe medical complications after delivery or other health conditions that contraindicate physical exercise (e.g., severe cardiovascular disease or musculoskeletal disorders).
  • Chronic hypertension or diabetes before pregnancy.
  • Current use of medication that could potentially affect cardiac function (e.g., medication for heart failure).
  • Received antibiotic treatment within the past month.
  • Severe mental health disorders that affect the ability to exercise.
  • Unable or unwilling to adhere to and attend the 12-week exercise program.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Postpartum Exercise Program

Participants will complete a 12-week exercise program consisting of three supervised sessions per week. Each session will combine moderate-intensity aerobic exercise, resistance training, and pelvic floor exercises. Exercise intensity will be adjusted to individual fitness levels and monitored using heart rate and ratings of perceived exertion.

Participants assigned to the exercise group will undertake a 12-week program comprising three supervised 60-minute sessions per week. Each session includes a 5-minute warm-up, 20 minutes of moderate-intensity aerobic exercise on a treadmill or stationary bicycle, 20 minutes of resistance training, 10 minutes of pelvic floor exercises, and a 5-minute cool-down. Exercise intensity will be individualized and progressively adjusted according to heart rate and rating of perceived exertion.

Kein Eingriff: Standard Postnatal Care

Participants will receive standard postnatal care, including routine health check-ups and general advice on postnatal health. They will not receive a structured exercise program as part of the study.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Systolic Blood Pressure
Zeitfenster: Before and after the 12-week exercise intervention

Systolic blood pressure will be measured in mmHg. Change from baseline to the end of the 12-week intervention will be assessed.

Before and after the 12-week exercise intervention
Change in Diastolic Blood Pressure
Zeitfenster: Baseline and 12 weeks

Diastolic blood pressure will be measured in mmHg using a validated automated device. Change from baseline to the post-intervention assessment will be assessed.

Baseline and 12 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Triglyceride Levels
Zeitfenster: Baseline and 12 weeks

Serum triglyceride levels will be determined using standard laboratory techniques. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Total Cholesterol Levels
Zeitfenster: Baseline and 12 weeks

Serum total cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed.

Baseline and 12 weeks
Change in High-Density Lipoprotein Cholesterol Levels
Zeitfenster: Baseline and 12 weeks

Serum high-density lipoprotein cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Low-Density Lipoprotein Cholesterol Levels
Zeitfenster: Baseline and 12 weeks

Serum low-density lipoprotein cholesterol levels will be determined using standard laboratory techniques. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Apolipoprotein A-I Levels
Zeitfenster: Baseline and 12 weeks

Apolipoprotein A-I levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Apolipoprotein A-II Levels
Zeitfenster: Baseline and 12 weeks

Apolipoprotein A-II levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Apolipoprotein B Levels
Zeitfenster: Baseline and 12 weeks

Apolipoprotein B levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Fasting Glucose Levels
Zeitfenster: Baseline and 12 weeks

Fasting glucose levels will be determined using standard laboratory tests. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Glycated Hemoglobin (HbA1c)
Zeitfenster: Baseline and 12 weeks

HbA1c will be determined using standard laboratory tests. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Fasting Insulin Levels
Zeitfenster: Baseline and 12 weeks

Fasting insulin levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in C-Peptide Levels
Zeitfenster: Baseline and 12 weeks

C-peptide levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Adiponectin Levels
Zeitfenster: Baseline and 12 weeks

Adiponectin levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Leptin Levels
Zeitfenster: Baseline and 12 weeks

Leptin levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in High-Sensitivity C-Reactive Protein Levels
Zeitfenster: Baseline and 12 weeks

High-sensitivity C-reactive protein levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Tumor Necrosis Factor-Alpha Levels
Zeitfenster: Baseline and 12 weeks

Tumor necrosis factor-alpha levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Interleukin-6 Levels
Zeitfenster: Baseline and 12 weeks

Interleukin-6 Levels Interleukin-6 levels will be measured using ELISA. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Fibrinogen Levels
Zeitfenster: Baseline and 12 weeks

Blood fibrinogen levels will be measured using a commercial ELISA kit. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Endothelin-1 Levels
Zeitfenster: Baseline and 12 weeks

Endothelin-1 Levels Endothelin-1 levels will be measured using a commercial ELISA kit. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Angiotensin II Levels
Zeitfenster: Baseline and 12 weeks

Angiotensin II levels will be measured using a commercial ELISA kit. Changes in levels will be assessed.

Baseline and 12 weeks
Change in Edinburgh Postnatal Depression Scale Score
Zeitfenster: Baseline and 12 weeks

Postpartum depressive symptoms will be assessed using the Edinburgh Postnatal Depression Scale (EPDS). Change in score from before to after the 12-week intervention will be assessed.

Baseline and 12 weeks
Change in 36-Item Short Form Health Survey Scores
Zeitfenster: Baseline and 12 weeks

Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36). Changes in questionnaire scores from before to after the 12-week intervention will be assessed.

Baseline and 12 weeks
Change in Pittsburgh Sleep Quality Index Score
Zeitfenster: Baseline and 12 weeks

Pittsburgh Sleep Quality Index Score Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Change in score from before to after the 12-week intervention will be assessed.

Baseline and 12 weeks
Change in Breastfeeding Self-Efficacy Scale-Short Form Score
Zeitfenster: Baseline and 12 weeks

Breastfeeding self-efficacy will be assessed using the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF). Change in score from before to after the 12-week intervention will be assessed.

Baseline and 12 weeks
Change in Six-Minute Walk Test Performance
Zeitfenster: Baseline and 12 weeks

Physical performance will be assessed using the Six-Minute Walk Test. Change from baseline to the post-intervention assessment will be assessed.

Baseline and 12 weeks
Change in Chair Stand Test Performance
Zeitfenster: Baseline and 12 weeks

Lower-body physical performance will be assessed using a Chair Stand test. Change from baseline to the post-intervention assessment will be assessed.

Baseline and 12 weeks
Change in Body Mass Index
Zeitfenster: Baseline and 12 weeks

Body mass index (BMI) will be measured. Change from baseline to the post-intervention assessment will be assessed.

Baseline and 12 weeks
Change in Fat Mass Percentage
Zeitfenster: Baseline and 12 weeks

Body fat percentage will be assessed at baseline and after the intervention. Changes from baseline to the post-intervention assessment will be evaluated.

Baseline and 12 weeks
Change in Lean Mass Percentage
Zeitfenster: Baseline and 12 weeks

Lean mass percentage will be assessed at baseline and after the intervention. The change from baseline to the post-intervention assessment will be evaluated.

Baseline and 12 weeks
Change in Vital Capacity
Zeitfenster: Baseline and 12 weeks

Change in vital capacity from baseline to the post-intervention assessment will be assessed.

Baseline and 12 weeks
Change in Plank Test Performance
Zeitfenster: Baseline and 12 weeks

Change in plank test performance from baseline to the post-intervention assessment will be assessed.

Baseline and 12 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

3. September 2026

Primärer Abschluss (Geschätzt)

30. September 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

2. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. November 2026

Zuerst gepostet (Tatsächlich)

6. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CREC Ref. No.: 2024.459

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren